Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

European Commission Gives Green Light To Bayer HealthCare's Flexyess

Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK) said the European Commission has issued its go ahead for the approval of the company's subgroup Bayer HealthCare's new low-dose combined oral contraceptive Flexyess. Based on the European Commission's positive decision, the Health Authorities of the EU Member States will grant national approvals in the coming weeks.

Flexyess will be the first low-dose combined oral contraceptive approved in the EU member states for a flexible extended regimen, offering women the option of 'personal period planning', meaning they can choose both the number and timing of their periods according to their needs.

Dr. Flemming Ornskov, chief marketing officer at Bayer HealthCare's Pharmaceuticals division, said, "Once Flexyess is launched, women will have the convenience and flexibility to influence the timing of their periods according to their individual needs."

Click here to receive FREE breaking news email alerts for Bayer AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
First-time claims for U.S. unemployment benefits fell by much more than anticipated in the week ended September 13th, according to a report released by the Labor Department on Thursday, with claims pulling back near the fourteen-year low set in July. After ending the previous session mostly higher, stocks may see some further upside in early trading on Thursday. The major index futures are currently pointing to a higher open for the markets, with the Dow futures up by 44 points. Banks took up less-than-expected amount of funds at the European Central Bank's first targeted longer term refinancing operation, damping hopes of the success of the measure that was aimed to boost liquidity to help revive lending to small businesses and households.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.